Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of “Buy” by Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned an average rating of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat reports. Nine research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have covered the stock in the last year is $171.00.

KRYS has been the topic of several research reports. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Guggenheim boosted their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Citigroup raised their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a report on Monday. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th.

Krystal Biotech Stock Down 2.1 %

Shares of KRYS opened at $155.68 on Friday. The firm has a market capitalization of $4.44 billion, a PE ratio of 1,946.24 and a beta of 0.85. The firm has a 50-day moving average price of $163.46 and a 200 day moving average price of $131.32. Krystal Biotech has a 52-week low of $82.09 and a 52-week high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The company had revenue of $42.14 million during the quarter, compared to analyst estimates of $27.43 million. During the same period in the prior year, the company posted ($1.25) earnings per share. On average, equities analysts expect that Krystal Biotech will post 1.89 EPS for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the transaction, the chief accounting officer now directly owns 12,936 shares in the company, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,087 shares of company stock valued at $6,210,591. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its position in shares of Krystal Biotech by 111.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after purchasing an additional 379 shares during the period. Quest Partners LLC bought a new position in Krystal Biotech in the 4th quarter worth $127,000. Pier 88 Investment Partners LLC acquired a new position in Krystal Biotech during the 4th quarter worth $145,000. Fox Run Management L.L.C. bought a new stake in Krystal Biotech during the third quarter valued at about $219,000. Finally, Capstone Investment Advisors LLC bought a new stake in Krystal Biotech during the fourth quarter valued at about $303,000. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).